Mylan N.V. (NASDAQ: MYL) and Parnell Pharmaceuticals Holdings (NASDAQ:PARN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.
Risk & Volatility
Mylan N.V. has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Parnell Pharmaceuticals Holdings has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500.
Insider and Institutional Ownership
71.6% of Mylan N.V. shares are owned by institutional investors. Comparatively, 16.9% of Parnell Pharmaceuticals Holdings shares are owned by institutional investors. 0.7% of Mylan N.V. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Mylan N.V. and Parnell Pharmaceuticals Holdings’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Mylan N.V.||$12.01 billion||1.37||$3.92 billion||$1.22||25.18|
|Parnell Pharmaceuticals Holdings||N/A||N/A||N/A||N/A||N/A|
Mylan N.V. has higher revenue and earnings than Parnell Pharmaceuticals Holdings.
This is a summary of recent recommendations for Mylan N.V. and Parnell Pharmaceuticals Holdings, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Parnell Pharmaceuticals Holdings||0||0||0||0||N/A|
Mylan N.V. presently has a consensus target price of $48.05, suggesting a potential upside of 56.42%. Given Mylan N.V.’s higher probable upside, equities analysts clearly believe Mylan N.V. is more favorable than Parnell Pharmaceuticals Holdings.
This table compares Mylan N.V. and Parnell Pharmaceuticals Holdings’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Parnell Pharmaceuticals Holdings||-130.46%||-83.86%||-43.24%|
Mylan N.V. beats Parnell Pharmaceuticals Holdings on 10 of the 10 factors compared between the two stocks.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.
Parnell Pharmaceuticals Holdings Company Profile
Parnell Pharmaceuticals Holdings Limited is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets. The Company operates through four segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. It augments its pharmaceutical products with its FETCH and mySYNCH software platforms. It offers disease-modifying product, Zydax, for the treatment of osteoarthritis (OA). Its reproductive hormone products include estroPLAN and GONAbreed. It has a nutraceutical product, Glyde. It also markets a non-steroidal anti-inflammatory drug (NSAID), called Tergive. It is developing a pipeline of clinical drug candidates, such as PAR 121, PAR 122, PAR 101, PAR 081 and PAR 061.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.